Gen2X enhances the RAIN RFID protocol with faster inventories, improved sensitivity/range, tighter read-zone confinement, and ...

While the goal is to reduce the cost burden on US patients, many in the industry are warning that there could be consequences ...

Increasingly complex cell therapy modalities, including multi-edit knock-in/knockout designs, are accelerating adoption of ...

The FDA has granted Compass Pathways with a rolling review for a New Drug Application (NDA) for its investigational ...

AbbVie received a Complete Response Letter (CRL) from the FDA for its Biologics License Application (BLA) for ...

In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license ...

The deal secures Lilly an in vivo gene therapy platform that could make CAR-T cell therapies accessible to a far broader ...

FDA is formalizing RWD as core evidence, enabling “single pivotal trial plus confirmatory evidence” approaches that may ...

Regeneron reached an agreement with the U.S. government to link current and future drug prices to those in other developed ...

Radiopharmaceutical pipelines are broadening beyond prostate cancer into multitumor programs, pairing alpha/beta emitters with immunotherapy or DDR agents and driving investments in isotope supply, ...

IV fluids like normal saline, dextrose, and sterile water are the most systemically dangerous shortages on the list, as they ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...